Prothena strengthens executive leadership with key appointments and strategic role transitions to support future growth
Prothena Corporation plc, a late-stage clinical biotechnology company focused on addressing diseases driven by protein dysregulation, has announced a series of leadership team updates aimed at strengthening its strategic and operational capabilities as it advances its pipeline of investigational therapies.
The company revealed that Annie Kingston has been promoted to the role of Chief Strategy Officer, while Michael Isaacs has been elevated to General Counsel and Corporate Secretary. These promotions reflect Prothena’s commitment to recognizing internal talent and aligning leadership expertise with its long-term growth objectives.
Mr. Isaacs will succeed Michael Malecek, who is set to depart the company after several years of service. His transition is expected to take place in June, at which point Mr. Isaacs will formally assume his new responsibilities. Meanwhile, Ms. Kingston’s promotion is effective immediately. Both executives will join Prothena’s senior leadership team and report directly to Gene Kinney, Ph.D., President and Chief Executive Officer.
In her new role as Chief Strategy Officer, Ms. Kingston will be responsible for shaping and executing Prothena’s overarching growth strategy. Her focus will include driving sustainable value creation, identifying opportunities to expand the company’s pipeline, and strengthening its position within the biotechnology sector. This includes advancing both wholly owned and partnered programs, as well as exploring collaborations and licensing opportunities that align with the company’s scientific expertise.
Mr. Isaacs, as General Counsel and Corporate Secretary, will serve as the company’s most senior legal officer. He will oversee all aspects of Prothena’s corporate legal function, ensuring compliance with regulatory requirements, managing legal risks, and supporting the company’s strategic initiatives from a governance perspective. His role will be critical as Prothena continues to grow and navigate the complex regulatory landscape associated with drug development.
Despite these changes, Tran Nguyen will continue in her role as Chief Financial Officer. Ms. Nguyen previously held a dual position as both CFO and Chief Strategy Officer, and her continued leadership in financial operations ensures continuity as strategic responsibilities transition to Ms. Kingston.
Commenting on the leadership updates, Dr. Kinney emphasized the company’s ongoing commitment to advancing its mission. He noted that Prothena remains focused on supporting its partnered clinical programs, investing in its internal preclinical pipeline, and leveraging its proprietary technologies to drive innovation. He highlighted Ms. Kingston’s contributions to the company’s evolving strategy and expressed confidence in her ability to further unlock the potential of Prothena’s preclinical programs and its CYTOPE® technology platform.
Dr. Kinney also acknowledged the contributions of Mr. Malecek, thanking him for his leadership over the past seven years. He pointed out that Mr. Malecek played a key role in succession planning, helping to ensure a smooth and seamless transition to Mr. Isaacs. Dr. Kinney expressed enthusiasm about continuing to work with Mr. Isaacs in his expanded role and praised both newly promoted executives for their significant contributions to the company to date. He concluded by stating that their leadership will be instrumental as Prothena executes its long-term strategic vision.
Executive Backgrounds
Ms. Kingston joined Prothena in 2023 and most recently served as Vice President of Corporate Strategy and Chief of Staff. During her tenure, she played an integral role in shaping the company’s strategic direction and supporting executive decision-making. Prior to joining Prothena, she worked at ClearView Healthcare Partners, a life sciences strategy consulting firm, where she held roles as Associate Principal and Project Leader between 2017 and 2023. In that capacity, she advised pharmaceutical and biotechnology companies on a range of strategic issues, including product development and corporate growth strategies. Earlier in her career, she was a consultant at The Dedham Group. Ms. Kingston holds a Bachelor of Arts degree in Biology and Psychology from Fairfield University.
Mr. Isaacs joined Prothena in 2020 and most recently served as Deputy General Counsel. In this role, he contributed to the company’s legal strategy and supported various corporate initiatives. Before joining Prothena, he was a Corporate Associate at Arnold & Porter Kaye Scholer LLP from 2015 to 2020, where he gained extensive experience in corporate law. Prior to his legal career, Mr. Isaacs held several research positions, including roles at the Salk Institute for Biological Studies and Biogen Idec, providing him with a strong scientific foundation that complements his legal expertise. He earned a Bachelor of Science degree in Biology (Microbiology) and a Master of Science degree in Biology (Biochemistry and Biophysics) from the University of California, San Diego, as well as a Juris Doctor from Santa Clara University School of Law.
Prothena Corporation plc is a biotechnology company focused on developing therapies for diseases associated with protein dysregulation, particularly neurodegenerative and rare peripheral amyloid conditions. With decades of scientific research underpinning its work, the company is dedicated to advancing innovative therapeutic candidates that have the potential to significantly alter disease progression.
Prothena’s pipeline includes a combination of wholly owned and partnered programs targeting a range of serious conditions, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and ATTR amyloidosis with cardiomyopathy, among others. The company leverages its deep understanding of neurological dysfunction and misfolded protein biology to identify novel targets and develop effective treatments.
A key component of Prothena’s innovation strategy is its proprietary CYTOPE® technology. This platform incorporates a cell-internalizing domain designed to enhance the delivery of macromolecular therapeutics directly into the cytosol, enabling highly specific targeting and improved therapeutic outcomes. By integrating this technology with its broader research capabilities, Prothena aims to expand the boundaries of treatment possibilities in complex diseases.
Overall, the recent leadership changes underscore Prothena’s focus on strengthening its executive team to support continued growth and innovation. By promoting experienced internal leaders and maintaining continuity in key roles, the company is positioning itself to effectively execute its strategic priorities and advance its mission of transforming the lives of patients affected by debilitating diseases.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying CYTOPE®, a novel technology that incorporates a cell-internalizing domain to drive efficient cytosolic delivery with highly specific marcomolecular effectors.
